Affordable Access

deepdyve-link
Publisher Website

Hemagglutinin from multiple divergent influenza A and B viruses bind to a distinct branched, sialylated poly-LacNAc glycan by surface plasmon resonance.

Authors
  • Bruce-Staskal, Pamela J1
  • Woods, Robert M2
  • Borisov, Oleg V3
  • Massare, Michael J4
  • Hahn, Timothy J5
  • 1 BioFactura, Inc. 8435 Progress Dr. Ste. Z, Frederick, MD 21701, USA(2). Electronic address: [email protected]
  • 2 Catalent Gene Therapy, 20 Firstfield Road, Gaithersburg, MD 20878, USA(2). Electronic address: robert[email protected]
  • 3 Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD 20878, USA. Electronic address: [email protected]
  • 4 Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD 20878, USA. Electronic address: [email protected]
  • 5 Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD 20878, USA. Electronic address: [email protected]
Type
Published Article
Journal
Vaccine
Publication Date
Sep 11, 2020
Identifiers
DOI: 10.1016/j.vaccine.2020.08.037
PMID: 32928588
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Influenza viruses initiate infection via specific interactions of hemagglutinin (HA) with host cell surface sialic acid-containing glycans. Antigenic drift has resulted in HA amino acid sequence changes that affect binding properties for sialic acids. Further, viral propagation in eggs and cell culture for vaccine production can yield variants with mutations that affect the conformation and affinity of HA for sialic acids. Therefore, influenza vaccine researchers and manufacturers need robust analytical methods to assess directly the ability of vaccine candidates to bind to their specific sialic acid ligand. We developed a surface plasmon resonance method that uses an extended, biantennary glycan terminating with α-2,6 linked sialic acids to bind influenza HA and assess this interaction. Recombinant HA (rHA) from both influenza A and B viruses isolated from 1999 to 2017 strongly and specifically bind this sialic acid ligand, suggesting the binding ability of divergent HA for this ligand is resistant to antigenic drift. Importantly, the method can differentiate between wild type and mutant rHA for which binding to this sialylated glycan and red blood cells in hemagglutination assays is compromised. We believe this method can be a powerful tool to screen influenza A and B vaccine candidates and final vaccine preparations for their functional ability to bind sialic acids, which allows manufacturers to identify preparations in which mutations that affect sialic acid binding have arisen during propagation. Evaluation of vaccine rHA antigen integrity by confirmation of the receptor binding site functionality is a prudent cautionary step to assure the antigenic quality of seasonal influenza vaccines. Copyright © 2020 Novavax, Inc. Published by Elsevier Ltd.. All rights reserved.

Report this publication

Statistics

Seen <100 times